
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Steven Galson, MD, has been appointed acting surgeon general beginning October 1, 2007.
Steven Galson, MD, has been appointed acting surgeon general beginning October 1, 2007. Galson, a Rear Admiral with the US Public Health Service, joined the FDA in April 2001 as the Center for Drug Evaluation and Research (CDER) deputy center director and was appointed director in July 2005. Janet Woodcock, MD, will become acting director at CDER until a permanent center director is found. She will retain her position as deputy commissioner and permanent chief medical officer.







